chevron_leftBack
As of 5 June 2026, Hanmi Pharm. Co., Ltd. has a market cap of $4.0B USD, ranking #4469 globally and #111 in South Korea.
It ranks #339 in the Healthcare sector, and #130 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$4.0BUSD
6.12T KRW
Enterprise Value
$4.26BUSD
6.53T KRW
Revenue (TTM)
$1.01BUSD
1.55T KRW
EBITDA (TTM)
$210.51MUSD
322.68B KRW
Net Income (TTM)
$110.62MUSD
169.55B KRW
EBITDA Margin
21%
Profit Margin
11%
PE Ratio
36.1
Forward PE
34.8
PS Ratio
4.0
PB Ratio
4.3
EV/EBITDA
20.2
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Jae-Hyun Park
open_in_new
Employees
2,400
Founded
1973
Website
hanmipharm.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -5.3% | -6.2% | -16% | -9% | 17% | 86% |
News
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
128940
한미약품(주)
ISIN: KR7128940004
Shares Out.:
Shares Outstanding:
12.689M1
Shares Float:
6.201M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
457,500 KRW |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Hanmi Pharm. Co., Ltd.
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
KRX: 0126Z0
|
$9.07B
127%
13.91T KRW
|
-
|
|
KRX: 000250
|
$6.72B
68%
10.3T KRW
|
1958.1
|
|
KRX: 326030
|
$5.2B
30%
7.97T KRW
|
29.9
|
|
KRX: 298380
|
$4.92B
23%
7.55T KRW
|
-
|
|
KRX: 000100
|
$4.51B
13%
6.92T KRW
|
35.9
|
|
KRX: 141080
|
$4.41B
10%
6.76T KRW
|
-
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
19K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
14K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
9K%
|
97.4
|
|
SIX: RO
|
$324.68B
8K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$289.43B
7K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$277.35B
7K%
218.9B CHF
|
20.5
|
chevron_leftBack